Preferred Label : Nivolumab/Relatlimab-rmbw;
NCIt synonyms : Relatlimab-rmbw/Nivolumab; Relatlimab-rmbw-Nivolumab; Nivolumab-Relatlimab-rmbw; Nivolumab and Relatlimab-rmbw; Relatlimab-rmbw and Nivolumab; Opdivo/Relatlimab-rmbw; Nivolumab/Relatlimab-rmbw Injectable Formulation; Nivolumab and Relatlimab;
NCIt definition : An injectable fixed-dose combination formulation composed of nivolumab, a human immunoglobulin
(Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell
surface receptor programmed death-1 (PD-1, PCD-1), and relatlimab-rmbw, a human IgG4
monoclonal antibody directed against the inhibitor receptor lymphocyte activation
gene-3 (LAG-3), with immune checkpoint inhibitory and antineoplastic activities. Upon
intravenous administration of nivolumab and relatlimab-rmbw, nivolumab binds to and
blocks the activation of PD-1 by its ligands programmed cell death ligand 1 (PD-L1),
which is overexpressed on certain cancer cells, and programmed cell death ligand 2
(PD-L2), which is primarily expressed on antigen-presenting cells (APCs). This prevents
PD-1-mediated signaling and PD-1-mediated inhibition of the immune response. Relatlimab
binds to LAG-3 on tumor infiltrating lymphocytes (TILs) and prevents LAG-3 binding
to major histocompatibility complex (MHC) class II. This prevents LAG-3-mediated signaling
and LAG-3-mediated inhibition of the immune response. Together, blocking these two
immune checkpoints re-activates the immune system, increases cytotoxic T-lymphocytes
(CTLs) proliferation and activation, and leads to a reduction in tumor growth. Activated
PD-1 negatively regulates T-cell activation and plays a key role in tumor evasion
from host immunity. LAG-3 expression on TILs is associated with tumor-mediated immune
suppression.;
Drug name : Opdualag;
Molecule name : BMS-986213; BMS 986213;
NCI Metathesaurus CUI : CL1778976;
Codes from synonyms : 59120;
Origin ID : C186440;
UMLS CUI : C5577550;
Semantic type(s)
- UMLS correspondences (same concept)
- chemical_or_drug_has_mechanism_of_action
- concept_is_in_subset
- has_target
- is_component_of_chemotherapy_regimen
